Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares
(NQ:
QNTM
)
22.46
+3.15 (+16.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares
< Previous
1
2
3
Next >
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Submits MS Drug Candidate to UK ILAP Program
July 08, 2025
Via
Investor Brand Network
TinyGemsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Submits MS Drug Candidate to UK ILAP Program
July 08, 2025
Via
Investor Brand Network
Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom
July 08, 2025
From
Quantum BioPharma
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Launches $600 Private Placement of Class A Multiple Voting Shares
June 30, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Backs Unbuzzd’s $5 Million Raise via Regulation D Offering
June 26, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
June 26, 2025
Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Brain and Alcohol Health Pipeline, Receives Phase 2 Trial Approval for FSD202
June 18, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
June 18, 2025
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies,...
Via
Newsfile
Topics
Initial Public Offering
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Begins First MS Patient Scan in MGH PET Imaging Study
June 17, 2025
Via
Investor Brand Network
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
June 17, 2025
Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302
From
Quantum BioPharma
Via
GlobeNewswire
TinyGemsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Plans Special Dividend Linked to Litigation Proceeds
June 13, 2025
Via
Investor Brand Network
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
June 13, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000
June 10, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Clarifies Name, Ownership, and RTO Rumors Involving unbuzzd
June 03, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
Quantum BioPharma Clarifies It Has Not Changed Its Name
June 03, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Finalizes $2.35 Million Settlement with Former CEO Raza Bokhari
May 30, 2025
Via
Investor Brand Network
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
May 30, 2025
Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces Auditor Appointment and Name Change for Unbuzzd Wellness
May 29, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
May 29, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives Australian Ethics Approval for Phase 2 Trial of FSD202 in MCAS Patients
May 28, 2025
Via
Investor Brand Network
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
May 28, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Taps BitGo to Safeguard Crypto Assets
May 21, 2025
Via
Investor Brand Network
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
May 21, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Signs Agreement to Advance MS Drug Toward Phase 2 Trial
May 20, 2025
Via
Investor Brand Network
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
May 20, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
May 19, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
May 16, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Completes Dosing in Key Toxicity Studies for MS Drug Candidate
May 12, 2025
Via
Investor Brand Network
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
May 12, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Files Amended $700M Market Manipulation Complaint in Federal Court
May 05, 2025
Via
Investor Brand Network
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.